From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Topics>
  3. Hepatitis>
  4. Archives

Hepatitis: Archives

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.

Items 101-125 of 402 are shown

A Blood Test for Subclinical Hepatic Encephalopathy?

In a pilot study of patients with cirrhosis, 3-nitro-tyrosine showed high accuracy in detecting or excluding MHE.

Adherence to HCV Therapy Is Associated with Virologic Response

Patients with better adherence to peginterferon and ribavirin showed better early and sustained virologic responses to HCV infection.

Should We Continue Entecavir for HBV Infection Despite Partial Virologic Response?

Results from a prospective cohort study found continued virologic response without viral resistance to entecavir despite PVR for up to 3 years.

Adherence to Hepatitis C Virus Therapy Improves Virologic Outcomes

At least for patients with genotype 1 or 4 infections, adhering to therapy improves response rates.

Child-Pugh Score Predicts Prognosis in Hepatitis C Virus Infection

Disease progression accelerates when Child-Pugh scores are ≥7.

Interferon-Free Regimen Shows Promise for Chronic HCV Infection

In a phase Ib trial, the combination of a polymerase inhibitor, a protease inhibitor, and ribavirin demonstrated potent antiviral activity.

Telaprevir Therapy for 24 Weeks Appropriate for Many with HCV Infection

Response-guided treatment with telaprevir, peginterferon alfa-2a, and ribavirin for 24 weeks was noninferior to the standard 48-week course in patients with hepatitis C virus infection.

New Options for HCV Treatment: Is Better Good Enough? — The Experts Respond

Two experts describe how they would manage our latest Antiretroviral Rounds case.

New Options for HCV Treatment: Is Better Good Enough?

An HIV/HCV-coinfected patient who had only a partial response and treatment-limiting adverse effects with prior peginterferon/ribavirin therapy is interested in the new HCV treatment options. Would you recommend them?

HCV Transmission in HIV-Positive MSM — Sex, Not Just Drugs

High-risk sexual behavior is associated with HCV transmission among HIV-positive men who have sex with men.

Another New Drug for Hepatitis C

Telaprevir boosted response rates substantially in patients with genotype 1 infection.

Patterns in HBV DNA and ALT Levels Predict Risk for Hepatocellular Carcinoma

Risk was higher in patients with chronic hepatitis B virus infection who had ever high-normal, transiently abnormal, or persistently abnormal HBV DNA or alanine aminotransferase levels.

Landmark Biomarker Studies Are Likely to Overstate Findings

Results of frequently cited studies often differ markedly from those of meta-analyses or studies in larger populations.

Telaprevir Markedly Improves HCV Genotype 1 Cure Rates

Final results of phase III trials show that telaprevir plus standard therapy with peginterferon alfa-2a and ribavirin was more effective than standard therapy alone.

Adding Entecavir to Tenofovir/FTC Works in Some HIV/HBV-Coinfected Patients

But the study was small, and the success of the intervention may be attributable to the low baseline rate of 3TC resistance.

Telaprevir Isn't Useful for All HCV Genotypes

Telaprevir-based triple therapy showed some promise against hepatitis C virus genotype 2 infection but had limited activity against genotype 3 infection.

Community-Based Primary Care Treatment of HCV Infection

PCPs treated hepatitis C virus infections as safely and effectively as multidisciplinary specialty care providers.

Cutaneous Lesions of Azathioprine Hypersensitivity Syndrome

These authors suggest that most cutaneous manifestations of azathioprine hypersensitivity represent neutrophilic dermatoses, but do they?

New Treatments for Chronic Hepatitis C Infection

The newly approved HCV protease inhibitors boceprevir and telaprevir promise to revolutionize HCV treatment.

Liver Transplantation in HIV-Infected Patients

Survival rates were 85% at 1 year and 64% at 5 years. The vast majority of patients were able to maintain HIV control following transplantation.

Lamivudine for Chronic Hepatitis B Virus Infection

Switching from entecavir to lamivudine led to more viral rebound and drug resistance in patients who first achieved undetectable HBV DNA levels with entecavir.

More May Be Better: HBV Vaccination in HIV-Infected Patients

Four doses of HBV vaccine resulted in higher seroconversion rates than the standard three-dose schedule.

Hepatitis C Week Is Upon Us

Dr. Paul Sax outlines the many "known unknowns" of new HCV treatments in his blog HIV and ID Observations.

New Treatment for Chronic Hepatitis C Infection?

Boceprevir, added to conventional therapy, raised response rates in patients with genotype 1.

Low-Dose Peginterferon as Maintenance Therapy for Hepatitis C-Infected Patients with Cirrhosis

Peginterferon alfa-2b did not prolong time to first occurrence of either clinical decompensation, hepatocellular carcinoma, liver transplant, or death.

Items 101-125 of 402 are shown

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?





Copyright © 2013. Massachusetts Medical Society. All rights reserved.